Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.7 (
DNA polymerase
)
17,007
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The efficient in vitro inhibition of hepatitis B virus
DNA polymerase
by trisodium phosphonoformate (PFA,
INN
: foscarnet sodium) and its low toxicity suggested that PFA could be used as a therapeutic agent for hepatitis B infection. PFA was also found to inhibit woodchuck hepatitis virus (WHV)
DNA polymerase
in vitro. As a model to test PFA's eventual effect, chronically WHV infected woodchucks were treated with PFA. The animals were treated twice daily in a dosage which gave a minimum serum level of PFA corresponding to an in vitro inhibiting effect on WHV
DNA polymerase
of about 40%. The concentration in liver tissue was found to be 15% below serum level. The amount of WHV particles in serum was followed by
DNA polymerase
assay. No effect on WHV production could be seen during 2 weeks' treatment. No change of the in vitro sensitivity to PFA of the WHV
DNA polymerase
was seen. These results indicate that the WHV associated
DNA polymerase
has no role in the production of viral particles.
...
PMID:No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production. 622 May 63